Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/696764


Singapore Pharmaceuticals and Healthcare Report Q1 2011


Description: The Singapore Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Singapore's pharmaceuticals and healthcare industry.

Demographic and epidemiological factors will shape the development of the Singaporean pharmaceutical market over the coming years. The city-state’s population is ageing rapidly and increasingly suffering from conditions such as diabetes and obesity-related problems, which require long-term treatment.

According to the latest National Health Survey, the obesity rate in Singapore rose to 10.8% during 2010, up from the 6.9% recorded in 2004. The Health Promotion Board (HPB) attributed the rising rate to a lack of physical activity coupled with a more sedentary lifestyle. The alarming rise has led the government to launch the National Healthy Lifestyle campaign.

In local currency terms, Singapore’s pharmaceutical market is forecast to reach SGD839mn (US$615mn) in 2010, thus rising by a low single-digit figure in relation to the calculated 2009 value. The market will post a local currency compound annual growth rate (CAGR) of 3.80% in the 2009-14 period, which will be characterised by the increased use of generics (with Indian firms to benefit from an improved registration pathway), patent expirations and a general focus on cost-containment. Growth figures will improve in the subsequent five years, with the market posting a 4.76% CAGR over the 2009-2019 period, reaching SGD1.31bn (US$1.03bn).
However, despite some positives, Singapore slipped from fourth to sixth place in BMI’s Asia Pacific Pharmaceutical Business Environment Ratings (BER) for Q111.

While Singapore’s consistent and transparent medicine regulations are attractive to multinational drugmakers, its fundamental drawback is a small and mature pharmaceutical market that is growing slowly, while strict price controls are also a deterrent. Over the medium term, we expect Singapore to fall down the ratings, as emerging countries such as Vietnam and Indonesia become more alluring to foreign firms selling patented products.

Nevertheless, Singapore's commitment to a low tax regime and high levels of investment in its infrastructure ensures that it has a superior business environment not only among its regional peers, but across the world. The authorities are aiming to boost its biotechnology industry, which will continue to provide a steady and expanding stream of pharmaceutical exports. The government is dedicated to attracting skilled migrants and foreign direct investment (FDI) in order to maintain its pre-eminence as a regional trade and financial hub, as well as enabling the economy to diversify into service industries. All this is being achieved in an environment of low corruption, minimal bureaucracy and good security, which will continue to provide strong attractions for foreign pharmaceutical companies.


Contents: Executive Summary
SWOT Analysis
Singapore Pharmaceuticals And Healthcare Industry SWOT
Singapore Political SWOT
Singapore Economic SWOT
Singapore Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q111
Rewards
Risks

Singapore – Market Summary
Regulatory Regime
Intellectual Property Issues
Trade Agreements
Pricing and Reimbursement
Industry Trends and Developments
Epidemiology
Non-Communicable Disease
Communicable Disease
Healthcare Sector
Healthcare Financing
Healthcare Insurance Developments
Healthcare Company Developments
Medical Tourism
Research and Development
Bioscience Sector
Recent Research and Development Activities
Clinical Trials
Recent Developments in Clinical Trials Industry
Medical Devices
Table: Classification Of Medical Devices In Singapore
Recent Developments in the Medical Devices Industry
Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales Indicators 2006-2014

Key Growth Factors – Industry
Table: Healthcare Expenditure Trends, Historical Data and Forecasts, 2006-2014
Key Growth Factors – Macroeconomic
Table: Singapore – Economic Activity
Prescription Drug Market Forecast
Table: Prescription Drug Sales Indicators 2006-2014
Patented Drug Market Forecast
Table: Patented Drug Sales Indicators 2006-2014
Generic Drug Market Forecast
Table: Generic Drug Sales Indicators 2006-2014
OTC Medicine Market Forecast
Table: OTC Medicine Sales Indicators 2006-2014
Medical Device Market Forecast
Table: Medical Device Sales Indicators 2006-2014
Pharmaceutical Trade Forecast
Table: Pharmaceutical Imports & Exports Indicators 2006-2014
Other Healthcare Data Forecasts

Key Risks to BMI’s Forecast Scenario
Competitive Landscape
Pharmaceutical Industry
Table: Singapore's Leading Healthcare And Pharmaceutical Companies According To Market Capitalisation
Domestic Pharmaceutical Sector
Domestic Pharmaceutical Output
Foreign Industry
Foreign Company Activities
Traditional Chinese Medicine
Pharmaceutical Distribution
Retail Pharmacies
Recent Developments in Pharmaceutical Supply Chain

Company Profiles

Indigenous Manufacturers
Haw Par
SciGen
MerLion Pharmaceuticals
Veredus Laboratories

Leading Multinationals
Pfizer
Novartis
GlaxoSmithKline
Sanofi-Aventis
Merck & Co
Baxter

Country Snapshot: Singapore Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2000-2030
Section 2: Education and Healthcare
Table: Education, 2000-2004
Table: Vital Statistics, 2005-2030
Section 3: Labour Market and Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)

BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources


Companies Mentioned -Pfizer -GlaxoSmithKline -Merck & Co -Novartis -Sanofi-Aventis -Baxter -Haw Par Corporation Ltd -SciGen Ltd -MerLion Pharmaceuticals -Veredus Laboratories


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/696764

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 16/02/2012 06:05:58
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Singapore Pharmaceuticals and Healthcare Report Q1 2011
Web Address:
http://www.researchandmarkets.com/reports/696764
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €393.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 16/02/2012 06:05:58

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)